Tohoku J. Exp. Med., 2009, 218 (3) , 165-175. © 2009 Tohoku University Medical Press Infection with the hepatitis C virus (HCV) represents a relevant human health problem, with an estimated human serum-prevalence of 1% worldwide. In most cases, HCV infection becomes chronic, causing chronic hepatitis, cirrhosis, or hepatic cancer (Pawlotsky 2004) . HCV is a virion of the family Flaviviridae, genus Hepacivirus, with a lipid envelope and a single-stranded RNA encoding a single polyprotein of about 3010 amino acids, which undergoes subsequent processing by host and viral enzymes to yield functional viral proteins (Choo et al. 1991; Giannini and Br échot 2003) . Structural proteins, such as the nucleocapsid C protein, two enveloped glycoproteins E1 and E2, and the p7 protein, are released from the polyprotein by host proteases. The remainder HCV polyprotein NS2/NS3/NS4A/ NS4B/NS5A/NS5B is further processed by NS2, a zincdependent protease, and NS3, a virus encoded serine-type protease. The NS3 protease domain is located at the N-terminal side of the protein (Kim et al. 1996; Lindenbach and Rice 2005) , whereas the C-terminal side has helicase function (Penin 2003) .
In addition to NS3, the NS4A protein is required for cleavage at the NS3/4A, NS4A/4B, and NS4B/5A junctions of the polyprotein, and it enhances the efficiency of cleavage at the NS5A/5B site (Failla et al. 1994; Bartenschlager et al. 1995; Gallinari et al. 1999; Lindenbach and Rice 2005) . The protease domain of NS3 consists of the first 181 amino acids forming a structure characteristic of the chymotrypsin family (Kim et al. 1996) . A key feature of NS3 is that it is supplied by the beta-strand structure of the NS4A protein (Kim et al. 1996; Bartenschlager 1999; Penin 2003) . The amino acid sequence of the NS4A central region, residues 21 to 34, makes all the contacts observed in the NS3-NS4A complex and is required for binding, thus enhancing NS3 proteolyt-ic activity (Lin et al. 1995; Tanji et al. 1995; Kim et al. 1996; Shimizu et al. 1996; Landro et al. 1997; Sardana et al. 1999) .
The processing of HCV polyprotein by NS3-NS4A represents a key target for development of anti-HCV compounds and several strategies exist to study this enzyme (Hamill and Jean 2005; Li et al. 2006; Beran and Pyle 2008) . Attempts to express NS3 and NS4A as separated proteins for reconstitution of NS3-NS4A complex did not lead to efficient protease activity and complementation of the protease domain of NS3, with the central region of the NS4A protein showing low protease activity Shimizu et al. 1996; Morgenstern et al. 1997; Beran and Pyle 2008) . Expression of the NS3 (1-631) -NS4A complex in eukaryotic systems yields small amounts of protein that are insufficient for extensive in vitro analysis (Sali et al. 1998; Taremi et al. 1998) . Taremi et al. (1998) developed a single-chain form of the NS3 protease fused to residues 21-GSVVIVGRIILS-32 of NS4A, through a linker (GSGS). This linker makes NS4A able to interact with NS3 through a beta-turn as in the natural full-length NS3 (1-631) -NS4A complex. The single-chain protein (NS4A (21-32) -GSGS-NS3 (3-181) ) expressed in Escherichia coli shows enzymatic parameters equivalent to those of the wild type NS3 (1-631) -NS4A protein generated in eukaryotic cells and can be over expressed to high levels as a soluble protein (Dimasi et al. 1998; Taremi et al. 1998; Howe et al. 1999; Leyssen et al. 2000; Wang et al. 2004; Kou et al. 2007) . In this study we identified, by DNA sequencing of the 4870-5902 nucleotide region, NS4A amino acid variants from serum samples of HCV infected patients; moreover, we performed amino acid modifications on the 21-32 NS4A sequence in order to understand better the role of NS4 as regulator in HCV replication. Our results indicate that amino acid I23 and/or C25 in NS4A variants lead to decreased protease activity of NS3. These findings may help in developing novel HCV anti-protease compounds.
Materials and Methods

Sera from blood donors infected with HCV
Thirteen sera were obtained from altruistic human blood donors at the Instituto Mexicano del Seguro Social, Puebla, Mexico, from March to September, 2006. These sera were analyzed for hepatitis C virus by a third generation enzyme immunoassay (Abbott Laboratories, Abbott Park IL, USA), and spared from transfusion. The study and strategy were approved by the Institutional Review Board of the program of Biomedical Sciences, México.
Cloning of HCV genes
The HCV RNA was extracted from serum samples with Trizol reagent (Invitrogen, Carlsbad, CA) . HCV sequences were obtained from RNA by Retro Transcription and Polymerase Chain Reaction (RT-PCR) assays with the Access RT-PCR System (Promega, Madison WI, USA), using oligonucleotides NS3-S and NS3-A for NS3, NS4A-S and NS4A-A for NS4A, NS3-S and NS3-NS4A-A for NS3-NS4A, and NS5AB-S and NS5AB-A for NS5AB (Table 1) . NS3 , NS3 (1-631) -NS4Awt (Table 1) . Similarly, NS5AB sequence was PCR amplified using oligonucleotides NS5AB-S and N5AB-A. These delimited fragments were double-digested with SacI and EcoRV, as was the expression vector PinPoint Xa-3 (Promega) and then gel-purified using the standard protocol for Wizard Plus SV Minipreps DNA Purification System (Promega). Each purified fragment was mixed with the expression vector, incubated 1 hr with T4 DNA ligase at 23°C, and then used to transform JM109 E. coli cells (Promega). E. coli cells with the expression vector were selected on Luria-Bertani (LB) agar plates with ampicillin (100 µ g/ml) and those with the desired sequence were identified by restriction analysis with SacI and EcoRV.
NS4A variants
For the purpose of cloning genes for expression of NS4Awt (21-32) -GSGS-NS3 , NS4A variants, and full-length NS3 (1-631) -NS4Am2 30-32 variant, the NS3 or NS3 (1-631) -NS4Am2 sequence was first cloned in the pCR 2.1-TOPO vector (Invitrogen). NS3 cDNA (3 µ l) was incubated with 1 µ l of pCR 2.1-TOPO and 1 µ l of salt solution (1.2 M NaCl and 0.06 M MgCl 2 ) for 10 min at 23°C. The product of this reaction was used to transform TOP10 E. coli cells (Invitrogen) following provider's recommendations. Transformed cells were detected on LB agar plates with ampicillin (100 µ g/ml) and the TOPO-NS3 or TOPO-NS3 (1-631) -NS4Am2 (1-54) plasmid was selected by restriction analysis (SacIEcoRV).
To simplify the construction of the sequences for expression of NS4Awt (21-32) -GSGS-NS3 , and NS4A variants, the TOPO-NS3 (1-181) sequence was used as PCR's starting template, and the wild type NS4A sequence 21-GSVVIVGRIILS-32 or its variants was introduced in two consecutive PCR rounds with the oligonucleotides listed in Table 1 . The first PCR round was used to introduce at the NS3 (1-181) 5´-end: i) the linker GSGS, and ii) the sequence for NS4A residues 26-32. The sequence obtained from this reaction was then used as template in the second PCR round used to introduce at the 5´-end: i) the sequence for the NS4A amino acid residues 21-25, ii) nucleotides for the IEGR amino acid sequence, and iii) a SacI restriction site. The PCR conditions were: 1x Pfu reaction buffer, 0.5 µ M oligonucleotides, 0.1 mM dNTP mix, 2.5 µ l template, 0.1 U Pfu DNA polymerase, and 0.25 mM MgSO 4 . The PCR parameters were: 50 sec at 95°C, 30 three-step cycles with 45 sec denaturation at 94°C, 1 min annealing at 55°C, and 2 min extension at 70°C.
To obtain the full-length NS3 (1-631) -NS4Am2 30-32 (1-54) variant, the TOPO-NS3 (1-631) -NS4Am2 (1-54) sequence was mutated by Gene Editor in vitro Site-Directed Mutagenesis System (Promega) protocol, using oligonucleotide NS3 (1-631) -NS4Am2 30-32 (1-54) -S, which induced mutagenesis in the amplified TOPO-NS3 (1-631) -NS4Am2 sequence and Selection Oligonucleotide Top Strand (Promega) ( Table  1) .
The plasmids 
Sequence analysis
All PCR constructs were sequenced from both ends. For NS4A a set of 10 individual clones was sequenced. The DNA nucleotide sequences were aligned with the sequence of HCV-1b (isolate HCV-BK; Simmonds et al. 1993 ) using Lasergene software (DNA Star, Madison, WI). The most abundant amino acid sequence from each NS4A set was determined as an NS4A variant.
Expression and purification of proteins
The PinPoint Xa-3 plasmids used to express NS3 , fulllength NS3 (1-631) -NS4A (1-54) , NS4A variants, and NS5AB lead to the production of these proteins fused at their N-terminal side to a tag that is biotinylated in vivo, and a proteolytic site IEGR between them, which allows removing the biotinylated tag from the native protein. Transformed JM109 E. coli cells were cultured on LB medium with ampicillin (100 µ g/ml) for 12 hrs at 37˚C. Protein expression was induced with isopropyl-beta-D-thiogalactopyranoside (IPTG) at a final concentration of 0.4 mM for 3 hrs at 23˚C. 
Underlined nucleotides represent the sequence for the NS4A amino acids inserted in each PCR round. S, Sense; A, Antisense.
The cells were harvested by centrifugation and resuspended in lysis buffer [50 mM Tris-HCl, pH 7.5, 3% glycerol, 5 mM dithiothreitol (DTT), 300 mM NaCl, 0.1% Tween 20]. The lysate was cleared by centrifugation at 12000 × g for 30 min and the supernatant was purified on an avidin coupled resin (Promega) following manufacturer's recommendations, with some modifications. The avidin coupled resin was washed 5 times with washing buffer (50 mM TrisHCl, pH 7.5, 3% glycerol, 1 mM DTT, 300 mM NaCl), mixed with the supernatant, and incubated for 3 hrs at 4°C. The resin was then washed three times with washing buffer and the avidin-biotin bound protein was recovered in B-buffer (25 mM Tris-HCl, pH 7.5, 5 mM biotin, 5% glycerol, 5 mM DTT, 200 mM NaCl) for 1 hr at 4°C. The pooled fractions, containing the biotin-tagged recombinant protein, were incubated with 0.5 µ g of Factor Xa (Promega) for 3 hrs at 21°C in a final 1-ml volume to remove the tag. The protein was incubated again in the avidin coupled resin for 1 hr at 4°C, recovering the protein as the unbound fraction. The fractions containing the expressed protein were selected by silver-stained SDS-polyacrylamide gel electrophoresis (PAGE) (Nielsen and Brown 1984) , and protein concentration was determined by Bradford assay (BioRad, Richmond, CA).
Assays of protease activity
The protease activity of the expressed NS3 (1-181) and NS4A variants: NS4Awt , a final concentration of 130 µ M NS5AB protein was used. Each one of these proteins was incubated in buffer (25 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM DTT, 0.01% Tween 20, 0.5 mM EDTA, 5% glycerol) at a final concentration of 2 µ M for 1 hr at 21°C. The reaction was quenched with 10% phosphoric acid followed by a denaturation step for 3 min at 95˚C. The samples were run in 12% SDS-PAGE with several dilutions of the NS5AB protein, silverstained (Nielsen and Brown 1984) , and analyzed by densitometry with the Quantity-One software (BioRad). The enzymatic activity was calculated as percentage of processed NS5AB with reference to the control with the same amount of substrate (band density processed NS5AB/band density NS5AB control × 100). All values represent at least three independent assays.
Results
Natural variants of NS4A
The nucleotide region 4870-5902 of the HCV genome, comprising the sequence for the NS4A protein, was analyzed in samples from 13 blood donors infected with HCV. The alignment of the NS4A PCR sequences with the HCV-1b sequence (isolate HCV-BK; Simmonds et al. 1993 ) revealed some variation in the amino acids of the NS4A central region. From the 13 samples evaluated, three variants were found: NS4Awt which is identical to the wild type HCV-1b sequence in the central region (21-GSVVIVGRIILS-32) but has three substitutions elsewhere (Fig. 1) , NS4Am2 with five substitutions in the central region (V23I, I25C, I30S, L31T, and S32L) and two elsewhere, and NS4Am3 with three substitutions in the central region (V23I, I25C, and I30V) and four elsewhere. The NS4Awt seems to be the major variant, since it was present in 11 blood donor's samples whereas NS4Am2 and NS4Am3 are minor variants, widely expressed each one in a single blood donor (accession No. FJ770083-FJ770199) (Fig. 1) .
Cloning and expression of the proteins NS3 and NS5AB of an HCV-infected blood donor
The effect of NS4A variants on the protease activity of NS3 was evaluated. The NS3 sequence from one of the HCV-infected blood donors was expressed in order to reconstitute a homologous system consisting of NS4A variants obtained from the same genetic background as the NS3 protease, since there is some variability in the NS3 amino acid sequence, even within the same genotype (Martell et al. 1992; Bukh et al. 1995; Pawlotsky 2003; Vallet et al. 2005) . We cloned and sequenced the NS3 protease domain (NS3 (1-181) ), as well as the full-length NS3 (1-631) -NS4A (1-54) sequence, from one HCV-infected blood donor (serum sample #3; accession No. EU980108, FJ895111, respectively). The NS3 amino acid sequence obtained shows 95% identity with the HCV-1b sequence (isolate HCV-BK; Simmonds et al. 1993) , and the NS4Am2 sequence (Fig. 1) . In order to develop a fully homologous system, the NS5AB sequence needed to produce the NS3 substrate was also cloned from the same Fig. 1 . Amino acid sequence of NS4A HCV-1b and variants. Three variants of the NS4A amino acid sequence given on the left were aligned with wild type HCV-1b (Simmonds et al. 1993 
EU980112). This sequence contains the required amino acids D/E-X-I-V/L-A-C/T | S/A-X-X-W/T for NS3
cleavage (Steinkühler et al. 1996) . Full-length NS3 (1-631) -NS4A (1-54) sequence from serum sample #4 was cloned and sequenced (accession No. FJ895110). This sample presents the NS4Awt sequence (Fig. 1) , and the NS3 amino acid sequence shows 95% identity with the isolate HCV-BK (Simmonds et al. 1993 ). All the NS3 amino acid sequences showed no changes in the first 40 amino acids used to bind the NS4A protein (data not shown).
The NS4Am2 variant reverses the enhancing effect of NS4A on NS3 (1-181) protease activity
We first determined by silver stained SDS-PAGE the purity and optimal amounts of each protein to be used in the assay (Fig. 2) . Densitometry analysis indicated that purity of all proteins was higher than 90%. Protease activity of the NS3 (1-181) was then assayed using the 40-kDa NS5AB protein as substrate of the reaction, and the product was analyzed by silver-stained SDS-PAGE. After digestion, fractions of 40 kDa, 30 kDa, and 21 kDa were identified, which correspond to NS5AB, the processed NS5AB, and NS3 , respectively (Fig. 3) . The protease activity of the NS3 (1-181) fused to the major variant NS4Awt sequence obtained in this study, which is identical to the NS4A HCV-1b sequence 21-GSVVIVGRIILS-32, processed 89% of the substrate (Fig. 3B, lane 7) . Hence, NS4Awt, enhances the protease activity of NS3 , as previously reported (Shimizu et al. 1996; Sardana et al. 1999; Lindenbach and Rice 2005) .
A NS4Am2 (21-32) -GSGS-NS3 (1-181) complex was constructed with the NS4Am2 sequence 21-GSIVCVGRISTL-32, which contains five amino acid changes in comparison to the wild type HCV-1b sequence (underlined). This complex processed 51% of the substrate, i.e., as low as the protease activity of the NS3 (1-181) protein alone (Fig. 3B) . This result suggests that these mutations in NS4A (I, C, S, T, and L) reversed the enhancing effect of this protein on the protease activity of NS3 . Due to the dependence on specific NS4A-NS3 interactions to enhance the protease activity of NS3, a structural prediction of the NS4Am2 21-GSIVCVGRISTL-32 sequence was made with the Lasergene software (DNA Star). The structural analysis showed a flexible region in the C-terminal side of the NS4Am2 beta-strand structure (Fig. 4B) that is produced by the change in amino acids I30S, L31T, and S32L, whereas other NS4A sequences from different HCV subtypes did not present this flexible region (data not shown). This specific modification in the NS4Am2 beta-strand may affect the number of contacts of NS4A with the NS3 structure.
Changes I30S, L31T, and S32L from variant NS4Am2 did not affect the enhancing effect of NS4A on NS3 protease activity An NS4Am2 30-32 amino acid sequence, 21-GSVVIVGRISTL-32, was constructed with the I30S, L31T, and S32L changes derived from the variant NS4Am2, i.e., containing three amino acid changes in comparison to the wild type HCV-1b sequence (underlined) that are assumed to modify the flexibility of the NS4A beta-strand structure (Fig. 4C) . The modified NS4A amino acid sequence was expressed fused to the NS3 protein as the NS4Am2 30-32 (21-32) -GSGS-NS3 complex, this complex processed 87% of the substrate (Fig. 3B) . The ability of NS4Am2 30-32 with amino acid changes, I30S, L31T, and S32L, to enhance the protease activity of NS3 suggests that they are not responsible for the failure of the NS4Am2 variant to stimulate the protease. Changes V23I and/or I25C from variant NS4Am2 reverse the enhancing effect of NS4A on NS3 protease activity
The NS4Am2 23,25 (21-32) -GSGS-NS3 (1-181) complex was expressed by fusing an NS4A 21-GSIVCVGRIILS-32 sequence to the NS3 protein. This complex contains two NS4A amino acid changes in comparison to the wild type HCV-1b sequence (underlined) and processed 53% of the substrate (Fig. 3B ). This NS4A variant was unable to enhance the protease activity obtained with the NS4Am2 30-32 variant. Hence, the NS4A changes, V23I and/or I25C, seem to be responsible for the failure of the NS4Am2 and NS4Am2 23,25 variants to enhance the protease activity of NS3 (1-181) . (1-181) protease alone or fused to NS4A variants were used, as indicated. B. Quantification of the enzymatic activity (band density of processed NS5AB/band density NS5AB control × 100) of at least three independent assays as in 3A.
The protease activity of full-length NS3 -NS4A complex is reduced by changes V23I and/or I25C from variant NS4Am2 Interdependence between the activity of the NS3 protease domain and NS3 helicase domain has been recently reported (Beran and Pyle 2008) . To analyze the effect of NS4A changes, V23I and/or I25C, on the protease activity of NS3 (1-631) , full-length NS3 (1-631) -NS4A (1-54) variants were expressed. These variants are formed by the two NS3 domains (protease-helicase; amino acids 1-631) and the full-length NS4A sequence (amino acids 1-54). Two fulllength NS3-NS4A variants were expressed using the sequence NS3 (1-631) -NS4Awt (1-54) (accession No. FJ895110) or NS3 (1-631) -NS4Am2 (1-54) (accession No. FJ895111). The protease activity of these two variants was different. The variant with the NS4Awt (1-54) sequence processed 81% of the substrate and that with the N4Am2 (1-54) sequence processed 47% of the substrate (Fig. 5B) . Since full-length NS4Am2 (1-54) sequence possesses five substitutions in the central region (amino acids 21 to 32) including V23I and I25C (Fig. 1 ), we performed a further assay to try to restore the enhancing effect of the NS4Am2 variant by changing the NS4A amino acids 23 and 25. The amino acids I23 and C25 on the NS4Am2 (1-54) sequence were changed to V23 and I25 as in the NS4Awt sequence. An NS3 (1-631) -NS4Am2 30-32 variant was obtained with I30S, L31T, and S32L changes in the NS4A central region. The protease activity of this variant was similar to that obtained with the NS4Awt (1-54) sequence (Fig. 5B) . These results reveal a similar effect of V23I and/or I25C changes in NS4A's central region on the protease activity of NS3 .
Discussion
Among the 13 HCV sequences obtained from March to September 2006, we identified two samples with NS4A variants of 5 and 3 amino acid differences in the 12 amino acid segment that did not enhance the protease activity of NS3. While the NS4Awt variant shows an NS4A sequence identical to the wild type HCV-1b in the central region (amino acids 21-32), the presence of NS4A sequence variants, obtained from two sera, revealed the existence of minor variants (termed m2 and m3) with substitutions in the central region. We cloned and sequenced NS4A independently 10 times from each serum sample of blood donors, in order to confirm each of the sequences to be expressed as recombinant proteins, and further assayed their effect on the proteolytic activity of NS3. This procedure warrants the natural origin of the m2 and m3 NS4A variants. NS4Awt sequence could exist in serum samples #3 and #8; however, the sequence analysis did not show it.
In this work, we analyzed the effect of natural variations in the amino acid sequence at residues 21 to 32 of NS4A on the protease activity of NS3. Different assay systems have been used to study the relation between NS4A and the protease function of NS3 (Lin et al. 1995; Shimizu et al. 1996; Taremi et al. 1998; Howe et al. 1999; Beran and Pyle 2008) ; enhancement of the NS3 protease activity by NS4A reported in all these studies agrees with our results.
Expression of the NS3 (1-181) as single protein or as a complex fused to NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) variants was accomplished by using Taremi's methodology, with some modifications, to obtain the single-chain NS4A (21-32) -GSGS-NS3 (1-181) complex (Taremi et al. 1998) . The fusion of the NS4A-NS3 sequences was divided in two PCR rounds, which facilitated the construction of NS4A variants. Recombinant proteins were expressed biotinylated, which in turn, allowed for a purification procedure under non-denaturing conditions using an avidin coupled resin. SDS-PAGE analysis of untagged purified proteins showed a molecular mass consistent with that predicted for native proteins. The simplicity of this methodology represents an alternative to explore the consequences of NS4A variants on the protease activity of NS3.
The five amino acid changes, V23I, I25C, I30S, L31T, and S32L, in the sequence of the NS4Am2 variant protein, were assayed fused to the N-terminus of the NS3 protease (amino acids 1-181) obtained from the same serum sample. In addition, two variants derived from NS4Am2 were assayed: i) the NS4Am2 30-32 variant with the amino acid changes I30S, L31T, and S32L, which represents a predicted structural modification in the NS4A beta-strand, and ii) the NS4Am2 23,25 variant with the amino acid changes V23I, I25C, that were common in the NS4A m2 and m3 variants. We hypothesized that the predicted structural modification in the NS4A beta-strand by the specific amino acid changes I30S, L31T, and S32L on the NS4Am2 variant may change the interaction of the NS4A C-terminus with the NS3 structure, generating a complex with low enzymatic activity. We found, however, that the NS4Am2 30-32 variant fused to NS3 enhanced the protease activity of NS3, as well as the wild type NS4A sequence. This result is consistent with a previous report on an experimental single change, L30S, in the NS4A that does not affect the protease activity of NS3 (Shimizu et al. 1996) . On the other hand, and contrary to our original hypothesis, the changes V23I, I25C in NS4A are common in the assayed complexes (with NS4Am2 variant and NS4Am2 23,25 variant) in which the NS4A sequence did not increase the protease activity of NS3.
The effect of NS4A variants on the protease activity of NS3 was analyzed by expressing the full-length NS3 (1-631) -NS4A sequence, since interdependence between NS3 domains (protease-helicase) has been reported (Dahl et al. 2007; Beran and Pyle 2008 ). An increment in the protease activity of full-length NS3 (1-631) -NS4Awt variant was observed as previously reported (Taremi et al. 1998; Howe et al. 1999; Beran and Pyle 2008) . Our results show a similar effect on the protease activity of NS3 , as well as NS3 , by amino acid changes in the central region of NS4A. This suggests a non-direct relation between the NS4A central region and the NS3 helicase domain and could be explained as due to the local rearrangements on the NS3 protease domain by NS4A binding (Yan et al. 1998) . The contact area between NS4A and the protease domain is through NS4A V23, I25, R28, I29, L31 amino acids, and I25 shows one of the largest surface areas buried within the NS3 structure (Kim et al. 1996; Yan et al. 1998 ). In the NS4Am2 sequence, I25 is substituted by C25. We propose that, as the structural prediction shows, the NS4Am2 beta-strand remains formed but the contact area with the protease is modified in residue NS4A 25, thus affecting nearby buried residues V23 and R28. This hypothesis suggests changes in 50% of the NS4A buried surface within NS3, because amino acid 23 is also substituted in NS4Am2 and NS4Am3 variants.
Since the NS4A I25 residue is important, as part of the NS4A central region for enhancing the NS3 protease activity, this residue has been related in experimental models with autoprocessing of NS3 (Butkiewicz et al. 1996; Kou et al. 2007; Hou et al. 2009) . In this report, we determined two NS4A variants with I25C substitution from blood donors infected with HCV; the analysis of these NS4A variants suggests that a mutation in I25 affects the protease activity of NS3. Taken together, these results suggest a regulatory-adaptive role on the protease activity of NS3 through mutations of the NS4A central region.
HCV in infected individuals have been described as mixtures of closely related but different viral populations referred to as quasispecies (Martell et al. 1992; Bukh et al. 1995; Vallet et al. 2005; López-Labrador et al. 2008) . Here, we identified minor variants of HCV that regulate in vitro the protease activity of NS3 at the NS5A/5B junction. Further assays are needed to determine if these in vitro findings are relevant in vivo, as well as in the processing of NS4A-dependent polyprotein cleavage sites. Since the protease activity of NS3 is required for the transforming activity of HCV in cell culture (Zemel et al. 2001) , NS4A variants are likely to be a factor in hepatic cancer.
